Catheter Precision Inc. has secured final regulatory clearance to sell its LockeT suture-retention device in the United Kingdom, completing the approvals it needed after obtaining a CE Mark for Europe in May 2025. The Fort Mill, South Carolina-based company said the UK registration allows immediate commercial launch of the Class 1 device, which is used to close venous puncture sites following cardiac electrophysiology procedures. The company will distribute LockeT through HC21, a UK distributor that generates about €180 million in annual revenue and employs more than 500 people across the UK and Ireland. The agreement extends an existing relationship between the two firms and gives Catheter Precision access to HC21’s established hospital network in a market that performs roughly 100,000 cardiac device procedures each year. Catheter Precision says LockeT’s intuitive design can improve patient comfort and enable earlier discharge, potentially helping the National Health Service shorten waiting lists by freeing hospital capacity. The UK approval expands the company’s European footprint and opens a significant commercial opportunity in the competitive cardiac electrophysiology sector.